The cost of hemophilia treatment: the importance of minimizing it without detriment to its quality
暂无分享,去创建一个
[1] P. Cortesi,et al. Cost-Effectiveness and Budget Impact of Emicizumab Prophylaxis in Haemophilia A Patients with Inhibitors , 2019, Thrombosis and Haemostasis.
[2] M. Solano,et al. Cost of Patients With Hemophilia A and High-Titer Inhibitors in Colombia. , 2019, Value in health regional issues.
[3] S. Corman,et al. Economic impact model of delayed inhibitor development in patients with hemophilia a receiving emicizumab for the prevention of bleeding events , 2019, Journal of medical economics.
[4] P. Pinto,et al. Haemophilia A: health and economic burden of a rare disease in Portugal , 2019, Orphanet journal of rare diseases.
[5] F. Peyvandi,et al. Burden of mild haemophilia A: Systematic literature review , 2019, Haemophilia : the official journal of the World Federation of Hemophilia.
[6] A. Hatswell,et al. Cost-Effectiveness Analysis of Recombinant Factor VIII Fc-Fusion Protein (rFVIIIFc) for the Treatment of Severe Hemophilia A in Italy Incorporating Real-World Dosing and Joint Health Data , 2019, PharmacoEconomics - Open.
[7] E. Neufeld,et al. Regional variation and cost implications of prescribed extended half‐life factor concentrates among U.S. Haemophilia Treatment Centres for patients with moderate and severe haemophilia , 2019, Haemophilia : the official journal of the World Federation of Hemophilia.
[8] G. Dolan,et al. Value of prophylaxis vs on‐demand treatment: Application of a value framework in hemophilia , 2018, Haemophilia : the official journal of the World Federation of Hemophilia.
[9] G. Cesana,et al. The socioeconomic burden of patients affected by hemophilia with inhibitors , 2018, European journal of haematology.
[10] P. Neumann,et al. Hemophilia Burden of Disease: A Systematic Review of the Cost-Utility Literature for Hemophilia , 2018, Journal of managed care & specialty pharmacy.
[11] R. Malouin,et al. Impact of the 340B Pharmacy Program on Services and Supports for Persons Served by Hemophilia Treatment Centers in the United States , 2018, Maternal and Child Health Journal.
[12] J. Gayle,et al. Burden of illness and costs among paediatric haemophilia patients with and without central venous access devices treated in US hospitals , 2018, Haemophilia : the official journal of the World Federation of Hemophilia.
[13] J. Jovanovic,et al. Cost-utility analysis of life-long prophylaxis with recombinant factor VIIIFc vs recombinant factor VIII for the management of severe hemophilia A in Sweden , 2018, Journal of medical economics.
[14] P. Lähteenmäki,et al. Long‐term clinical and economic outcomes in previously untreated paediatric patients with severe haemophilia A: A nationwide real‐world study with 700 person‐years , 2018, Haemophilia : the official journal of the World Federation of Hemophilia.
[15] S. Meunier,et al. Individualized PK‐based prophylaxis in severe haemophilia , 2018, Haemophilia : the official journal of the World Federation of Hemophilia.
[16] B. Tortella,et al. Real-World Analysis of Dispensed IUs of Coagulation Factor IX and Resultant Expenditures in Hemophilia B Patients Receiving Standard Half-Life Versus Extended Half-Life Products and Those Switching from Standard Half-Life to Extended Half-Life Products , 2018, Journal of managed care & specialty pharmacy.
[17] X. Zhang,et al. Influence of medical insurance schemes and charity assistance projects on regular prophylaxis treatment of the boys with severe haemophilia A in China , 2018, Haemophilia : the official journal of the World Federation of Hemophilia.
[18] A. Messori. Inhibitors in Hemophilia A: A Pharmacoeconomic Perspective , 2017, Seminars in Thrombosis and Hemostasis.
[19] G. Cesana,et al. Modern Treatments of Haemophilia: Review of Cost-Effectiveness Analyses and Future Directions , 2018, PharmacoEconomics.
[20] P. Cortesi,et al. Cost-effectiveness analysis of pharmacokinetic-driven prophylaxis vs. standard prophylaxis in patients with severe haemophilia A , 2017, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[21] M. Nichol,et al. Economic Burden of Illness among Persons with Hemophilia B from HUGS Vb: Examining the Association of Severity and Treatment Regimens with Costs and Annual Bleed Rates. , 2017, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[22] J. Carneiro,et al. Comparing the burden of illness of haemophilia between resource‐constrained and unconstrained countries: the São Paulo–Toronto Hemophilia Study , 2017, Haemophilia : the official journal of the World Federation of Hemophilia.
[23] J. Epstein,et al. Estimating the potential cost of a high dose immune tolerance induction (ITI) therapy relative to the cost of a combined therapy of a low dose ITI therapy with bypassing agent prophylaxis , 2017, Haemophilia : the official journal of the World Federation of Hemophilia.
[24] K. Batt,et al. Real‐world resource use and costs of haemophilia A‐related bleeding , 2017, Haemophilia : the official journal of the World Federation of Hemophilia.
[25] David Hughes,et al. The cost of severe haemophilia in Europe: the CHESS study , 2017, Orphanet Journal of Rare Diseases.
[26] K. Mukherjee,et al. Cost-Benefit Analysis and Assessment of Quality of Care in patients with Hemophilia undergoing treatment at National Rural Health Mission in Maharashtra, India. , 2017, Value in health regional issues.
[27] M. Toumi,et al. Cost‐effectiveness analysis of late prophylaxis vs. on‐demand treatment for severe haemophilia A in Italy , 2017, Haemophilia : the official journal of the World Federation of Hemophilia.
[28] P. Giangrande,et al. Making economic evaluations more helpful for treatment choices in haemophilia , 2017, Haemophilia : the official journal of the World Federation of Hemophilia.
[29] K. Johnston,et al. Budget Impact Analysis of Prolonged Half-Life Recombinant FVIII Therapy for Hemophilia in the United States. , 2017, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[30] H. Rasekh,et al. Cost-Effectiveness Analysis of Biogeneric Recombinant Activated Factor VII (AryoSeven™) and Activated Prothrombin Complex Concentrates (FEIBA™) to Treat Hemophilia A Patients with Inhibitors in Iran , 2016, Iranian journal of pharmaceutical research : IJPR.
[31] Sheh-Li Chen. Economic costs of hemophilia and the impact of prophylactic treatment on patient management. , 2016, The American journal of managed care.
[32] J. Hay,et al. A Budget Impact Model of Hemophilia Bypassing Agent Prophylaxis Relative to Recombinant Factor VIIa On-Demand. , 2016, Journal of managed care & specialty pharmacy.
[33] P. Cortesi,et al. Immune tolerance induction in patients with haemophilia a and inhibitors: effectiveness and cost analysis in an European Cohort (The ITER Study) , 2016, Haemophilia : the official journal of the World Federation of Hemophilia.
[34] M. Carvalho,et al. Costs and utilization of treatment in patients with hemophilia , 2015, BMC Health Services Research.
[35] Aris Angelis,et al. Socio-economic burden of rare diseases: A systematic review of cost of illness evidence. , 2015, Health policy.
[36] A. Farrugia,et al. Issues in assessing products for the treatment of hemophilia – the intersection between efficacy, economics, and ethics , 2015, Journal of blood medicine.
[37] M. Álvarez‐Román,et al. Cost analysis of prophylaxis with activated prothrombin complex concentrate vs. on‐demand therapy with activated factor VII in severe haemophilia A patients with inhibitors, in Spain , 2015, Haemophilia : the official journal of the World Federation of Hemophilia.
[38] D. Dalton. Hemophilia in the managed care setting. , 2015, The American journal of managed care.
[39] S. Donfield,et al. A haemophilia disease management programme targeting cost and utilization of specialty pharmaceuticals , 2014, Haemophilia : the official journal of the World Federation of Hemophilia.
[40] M. Penka,et al. Economic evaluation of rFVIIa high initial dose compared to rFVIIa standard initial dose in patients with haemophilia with inhibitors using the Czech HemoRec registry. , 2014, Thrombosis research.
[41] V. Jiménez‐Yuste,et al. Cost‐effectiveness of recombinant activated factor VII vs. plasma‐derived activated prothrombin complex concentrate in the treatment of mild‐to‐moderate bleeding episodes in patients with severe haemophilia A and inhibitors in Spain , 2013, Haemophilia : the official journal of the World Federation of Hemophilia.
[42] J. Hay,et al. Bypass therapy assay testing as a strategy to reduce costs for treatment of haemophilia patients with inhibitors , 2013, Haemophilia : the official journal of the World Federation of Hemophilia.
[43] P. Smejkal,et al. Economic analysis of recombinant activated factor VII versus plasma-derived activated prothrombin complex concentrate in mild to moderate bleeds: haemophilia registry data from the Czech Republic. , 2012, Thrombosis research.
[44] M. Escobar,et al. Utilization patterns and associated costs of factor assistance programmes among persons with haemophilia: a single institution review , 2012, Haemophilia : the official journal of the World Federation of Hemophilia.
[45] Kathleen A. Johnson,et al. Costs of care in hemophilia and possible implications of health care reform. , 2011, Hematology. American Society of Hematology. Education Program.
[46] H. Rasekh,et al. Cost-utility analysis of immune tolerance induction therapy versus on-demand treatment with recombinant factor VII for hemophilia A with high titer inhibitors in Iran , 2011, ClinicoEconomics and outcomes research : CEOR.
[47] J. Hay,et al. Economical comparison of APCC vs. rFVIIa for mild‐to‐moderate bleeding episodes in haemophilia patients with inhibitors , 2011, Haemophilia : the official journal of the World Federation of Hemophilia.
[48] C. Leissinger,et al. Modeling costs and outcomes associated with a treatment algorithm for problem bleeding episodes in patients with severe hemophilia a and high-titer inhibitors. , 2011, American health & drug benefits.
[49] J. Hay,et al. Systematic literature review of economics analysis on treatment of mild-to-moderate bleeds with aPCC versus rFVIIa , 2011, Journal of medical economics.
[50] M. Escobar. Health economics in haemophilia: a review from the clinician’s perspective , 2010, Haemophilia : the official journal of the World Federation of Hemophilia.